Document Type : Original Article


1 Department of Gastroenterology and Tropical Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt

2 Fever Hospital, Ministry of Health, Sohag, Egypt

3 Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt


Background: The increasing incidence of hepatocellular carcinoma (HCC) is a challenging health problem worldwide with poor prognosis and limited treatment options. The association between metabolic factors and HCC has been documented, however, there is a shortage of data about this association in our locality. Therefore, we aimed to determine the pattern of lipid profile in cirrhotic patients with HCC and investigate the association between dyslipidemia and HCC.
Method: In this case-control hospital-based study, serum lipid profile [total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-density lipoprotein (VLDL)] was determined in 100 patients with cirrhosis and 100 patients with cirrhosis and HCC. Multivariate analysis of HCC risk factors was done.
Results: Metabolic syndrome, hypertriglyceridemia, hypercholesterolemia, high LDL, and combined dyslipidemia were significantly more frequent in HCC patients than non-HCC patients. Low HDL and dyslipidemia were significantly associated with the late HCC stages and LDL levels were significantly correlated with α- fetoprotein levels. There was a tendency towards increasing the values of the other lipid parameters in advanced stages. Metabolic syndrome and combined dyslipidemia were associated with HCC risk.
Conclusion: Deranged lipid profiles were common in HCC patients. Metabolic syndrome and combined dyslipidemia could be potential risk factors for HCC and may offer a useful strategy for risk stratification; thus, their control can reduce the HCC burden.


How to cite this article:

Abdo Moustafa EF, Hassan EA, Mahmoud MM, Mahmoud AA, Ghaliony MAA. Deranged lipid profiles and hepatocellular carcinoma: clinical significance and association. Middle East J Cancer. 2022;13(2):275-84. doi: 10.30476/mejc.2021.86476.1346.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent
J, Jemal A. Global cancer statistics, 2012. CA Cancer
J Clin. 2015; 65(2): 87-108. doi: 10.3322/caac.21262.
2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma.
Lancet. 2018;391(10127):1301-14. doi: 10.1016/
3. Villanueva A. Hepatocellular carcinoma. N Engl J
Med. 2019;380(15):1450-62. doi: 10.1056/NEJMra
4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers
C, Rebelo M, et al. Cancer incidence and mortality
worldwide: Sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-
86. doi: 10.1002/ijc.29210.
5. Le GM, Biagini MR, Tarocchi M, Polvani S, Galli A.
Chemotherapy for hepatocellular carcinoma: the
present and the future. World J Hepatol. 2017;9(21):
907-20. doi: 10.4254/wjh.v9.i21.907.
6. Argyrou C, Moris D, Vernadakis S. Hepatocellular
carcinoma development in non-alcoholic fatty liver
disease and non-alcoholic steatohepatitis. Is it going
to be the “Plague” of the 21st century? A literature
review focusing on pathogenesis, prevention and
treatment. J BUON. 2017;22(1):6-20.
7. Reeves HL, Zaki MYW, Day CP. Hepatocellular
carcinoma in obesity, type 2 diabetes, and NAFLD.
Dig Dis Sci. 2016;61(5):1234-45. doi: 10.1007/s10620-
8. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts
LR, Kim WR. Diabetes mellitus heightens the risk of
hepatocellular carcinoma except in patients with
hepatitis c cirrhosis. Am J Gastroenterol. 2016;111(11):
1573-80. doi: 10.1038/ajg.2016.330.
9. Lewis GF, Rader DJ. New insights into the regulation
of HDL metabolism and reverse cholesterol transport.
Circ Res. 2005;96(12):1221-32. doi: 10.1161/01.RES.
10. Fiorenza AM, Branchi A, Sommariva D. Serum
lipoprotein profile in patients with cancer. A comparison
with non-cancer subjects. Int J Clin Lab Res. 2000;
30(3):141-5. doi: 10.1007/s005990070013.
11. Muntoni S, Atzori L, Mereu R, Satta G, Macis MD,
Congia M, et al. Serum lipoproteins and cancer. Nutr
Metab Cardiovasc Dis. 2009;19(3):218-25. doi:
12. Usman H, Rashid R, Ameer F, Iqbal A, Zaid M.
Revisiting the dyslipidemia associated with
acuteleukemia. Clin Chim Acta. 2015;444:43-9. doi:
13. Akinyemiju T, Abera S, Ahmed M, Alam N,
Alemayohu MA, Allen C, et al. The burden of primary
liver cancer and underlying etiologies from 1990 to
2015 at the global, regional, and national level. JAMA Oncol. 2017;3(12):1683-91. doi: 10.1001/jamaoncol.2017.3055.
14. El Zayadi AR, Badran HM, EMF B, Attia Mel- D,
Shawky S, Mohamed MK, et al. Hepatocellular
carcinoma in Egypt: a single center study over a
decade. World J Gastroenterol. 2005;11(33):5193-8.
doi: 10.3748/wjg.v11.i33.5193.
15. Bruix J, Sherman M. Management of hepatocellular
carcinoma: an update. Hepatology. 2011;53(3):1020-
2. doi: 10.1002/hep.24199
16. Bruix J, Sherman M, Llovet JM, Beaugrand M,
Lencioni R, Burroughs AK, et al. EASL Panel of
Experts on HCC. Clinical management of
hepatocellular carcinoma. Conclusions of the
Barcelona-2000 EASL conference. European
Association for the Study of the Liver. J Hepatol.
2001;35(3):421-30. doi: 10.1016/s0168-8278(01)
17. Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults. Executive
summary of the third report of The National Cholesterol
Education Program (NCEP) expert panel on detection,
evaluation, and treatment of high blood cholesterol
in adults (Adult treatment panel III). JAMA.
2001;285(19):2486-97. doi: 10.1001/jama.285.19.2486.
18. George P, Ludvik B. Lipids and diabetes. J Clin Basic
Cardiol. 2000;3(3):159-62.
19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr,
Clark LT, Hunninghake DB, et al. Implications of
recent clinical trials for the National Cholesterol
Education Program Adult Treatment Panel III
guidelines. Circulation. 2004;110(2):227-39. doi:
20. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano
D. Metabolic syndrome and risk of cancer: a systematic
review and meta-analysis. Diabetes Care.
2012;35(11):2402-11. doi: 10.2337/dc12-0336.
21. Russo A, Autelitano M, Bisanti L. Metabolic syndrome
and cancer risk. Eur J Cancer. 2008;44(2):293-7. doi:
22. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB,
Davila JA, McGlynn KA. Metabolic syndrome
increases the risk of primary liver cancer in the United
States: a study in the SEER-Medicare database.
Hepatology. 2011;54(2):463-71. doi: 10.1002/hep.
23. Fernandes JV, Cobucci RN, Jatoba CA, Fernandes
TA, de Azevedo JW, de Araujo JM. The role of the
mediators of inflammation in cancer development.
Pathol Oncol Res. 2015;21(3):527-34. doi: 10.1007/
24. Sohda T, Iwata K, Kitamura Y, Suzuki N, Takeyama
Y, Irie M, et al. Reduced expression of low-density
lipoprotein receptor in hepatocellular carcinoma with
paraneoplastic hypercholesterolemia. J Gastroenterol
Hepatol. 2008;23(7Pt2):e153-e6. doi: 10.1111/j.1440-
25. Alsabti' EAK. Serum lipids in hepatoma. Oncology.
1979;36(1):11-4. doi: 10.1159/000225310.
26. Qu Q, Wang S, Chen S, Zhou L, Rui JA. Prognostic
role and significance of paraneoplastic syndromes in
patients with hepatocellular carcinoma. Am Surg.
27. Alpert ME, Hutt MSR, Davidson CS. Primary
hepatoma in Uganda. A prospective clinical and
epidemiologic study of forty six patients. AM J Med.
1969;46(5):794-802. doi: 10.1016/0002-9343(69)
28. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang
FY, et al. Clinical characteristics and prognosis of
hepatocellular carcinoma patients with paraneoplastic
syndromes. Hepatogastroenterology. 2002;49(47):1315-9.
29. Ahaneku JE, Olubuyide IO, Taylor GO, Agbedana
EO. Abnormal lipid and lipoprotein patterns in liver
cirrhosis with and without hepatocelluiar carcinoma.
J Pak Med Assoc. 1992;42(11):260-3.
30. Motta M, Giugno I, Ruello P, Pistone G, Di Fazio I,
Malaguarnera M. Lipoprotein (a) behavior in patients
with hepatocellular carcinoma. Minerva Med.
31. Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is
modified by a farnesyl isoprenoid. Proc Natl Acad
Sci (USA). 1989;86(21):8323-7. doi: 10.1073/pnas.
32. Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T.
Clinical significance of abnormal lipoprotein patterns
in liver diseases. Int J Mol Med. 2005;15(4):655-60.
33. Kita T, Brown MS, Bilheimer DW, Goldstein JL.
Delayed clearance of very low density and intermediate
density lipoproteins with enhanced conversion to low
density lipoprotein in WHHL rabbits. Proc Natl Acad
Sci (USA). 1982;79(18):5693-7. doi: 10.1073/pnas.
34. Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer
on lipid and lipoprotein metabolism. Lipids Health
Dis. 2006;3;5:4. doi: 10.1186/1476-511X-5-4.
35. Kanel GC, Radvan G, Peters RL. High-density
lipoprotein cholesterol and liver disease. Hepatology.
1983;3(3):343-8. doi: 10.1002/hep.1840030311.
36. Huang J, Li L, Lian J, Schauer S, Vesely PW, Kratky
D, et al. Tumor-induced hyperlipidemia contributes
to tumor growth. Cell Rep. 2016;15(2):336-48. doi:
37. Moucari R, Asselah T, Cazals-Hatem D. Insulin
resistance in chronic hepatitis C: association with
genotypes 1 and 4, serum HCV RNA, and liver fibrosis.
Gastroenterology. 2008;134(2):416-23. doi:
38. Wedemeyer I, Bechmann LP, Odenthal M, Jochum
C, Marquitan G, Drebber U, et al. Adiponectin inhibits
steatotic CD95/Fas up-regulation by hepatocytes:
therapeutic implications for hepatitis C. J Hepatol.
2009;50(1):140-9. doi: 10.1016/j.jhep.2008.08.023.
39. Serfaty L, Poujol-Robert A, Carbonell N, Chazouilleres
O, Poupon RE, Poupon R. Effect of the interaction
between steatosis and alcohol intake on liver fibrosis
progression in chronic hepatitis C. Am J Gastroenterol.
2002;97(7):1807-12. doi: 10.1111/j.1572-0241.2002.
40. Menendez JA, Lupu R. Fatty acid synthase and the
lipogenic phenotype in cancer pathogenesis. Nat Rev
Cancer. 2007;7(10):763-77. doi: 10.1038/nrc2222.